AxoGen, Inc. $AXGN Shares Newly Acquired by White Pine Capital LLC

White Pine Capital LLC acquired a new position in shares of AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 43,219 shares of the medical equipment provider’s stock, valued at approximately $1,812,000. White Pine Capital LLC owned 0.07% of AxoGen at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of AxoGen by 163.7% during the third quarter. Russell Investments Group Ltd. now owns 334,902 shares of the medical equipment provider’s stock worth $14,039,000 after buying an additional 207,916 shares in the last quarter. Lisanti Capital Growth LLC raised its position in AxoGen by 21.9% in the 3rd quarter. Lisanti Capital Growth LLC now owns 110,420 shares of the medical equipment provider’s stock valued at $4,629,000 after buying an additional 19,855 shares during the last quarter. Advisor Resource Council lifted its stake in AxoGen by 6.8% in the 3rd quarter. Advisor Resource Council now owns 8,749 shares of the medical equipment provider’s stock valued at $367,000 after acquiring an additional 556 shares in the last quarter. Calamos Advisors LLC lifted its stake in AxoGen by 15.8% in the 3rd quarter. Calamos Advisors LLC now owns 110,210 shares of the medical equipment provider’s stock valued at $4,620,000 after acquiring an additional 15,064 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in AxoGen by 46.0% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 30,150 shares of the medical equipment provider’s stock valued at $1,264,000 after acquiring an additional 9,500 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the transaction, the director owned 10,650 shares of the company’s stock, valued at $529,305. The trade was a 24.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is owned by company insiders.

AxoGen Price Performance

NASDAQ:AXGN opened at $55.93 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.67 and a current ratio of 12.02. The stock’s 50-day simple moving average is $43.27 and its 200 day simple moving average is $40.44. The company has a market cap of $3.34 billion, a P/E ratio of -86.05 and a beta of 1.21. AxoGen, Inc. has a 52-week low of $23.00 and a 52-week high of $59.72.

AxoGen (NASDAQ:AXGN – Get Free Report) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. The business had revenue of $75.83 million for the quarter, compared to analyst estimates of $73.45 million. As a group, sell-side analysts forecast that AxoGen, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

AXGN has been the subject of a number of recent research reports. Citizens Jmp upped their price target on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Thursday, July 30th. HC Wainwright lifted their price objective on shares of AxoGen from $53.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of AxoGen in a research report on Wednesday, October 28th. Mizuho set a $65.00 price objective on shares of AxoGen in a research report on Wednesday, October 28th. Finally, Canaccord Genuity Group increased their target price on shares of AxoGen from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and an average target price of $57.92.

Read Our Latest Research Report on AXGN

AxoGen Profile

(Free Report)

AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.

Read More

Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.